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sulfate and heparin–protein interactions†
Ryan J. Weiss,a Philip L. S. M. Gordts,b Dzung Le,cd Ding Xu,e Jeffrey D. Eskobd
and Yitzhak Tor*ad
Surfen, bis-2-methyl-4-amino-quinolyl-6-carbamide, was previously reported as a small molecule
antagonist of heparan sulfate (HS), a key cell-surface glycosaminoglycan found on all mammalian cells.
To generate structure–activity relationships, a series of rationally designed surfen analogs was
synthesized, where its dimeric structure, exocyclic amines, and urea linker region were modified to
probe the role of each moiety in recognizing HS. An in vitro assay monitoring inhibition of fibroblast
growth factor 2 binding to wild-type CHO cells was utilized to quantify interactions with cell surface HS.
The dimeric molecular structure of surfen and its aminoquinoline ring systems was essential for its
interaction with HS, and certain dimeric analogs displayed higher inhibitory potency than surfen and
were also shown to block downstream FGF signaling in mouse embryonic fibroblast cells. These
molecules were also able to antagonize other HS–protein interactions including the binding of soluble
RAGE to HS. Importantly, selected molecules were shown to neutralize heparin and other heparinoids,
including the synthetic pentasaccharide fondaparinux, in a factor Xa chromogenic assay and in vivo in
mice. These results suggest that small molecule antagonists of heparan sulfate and heparin can be of
therapeutic potential for the treatment of disorders involving glycosaminoglycan–protein interactions.Introduction
Heparan sulfate proteoglycans (HSPGs) are expressed on virtu-
ally all animal cells and in the extracellular matrix. Each HSPG
consists of a core protein with one or more covalently attached
linear heparan sulfate (HS) chains composed of alternating
glucosamine and uronic acids that are heterogeneously N- and
O-sulfated (Fig. 1). These complex cell surface carbohydrates
regulate important biological processes including cell prolifer-
ation and motility, development, and organ physiology through
their interaction with a large number of matrix proteins and
growth factors.1–3 Sometimes these processes go awry, for
example in cancer, inammation and neurodegenerative
disorders.4,5 Thus, much interest exists in agents controlling, University of California, San Diego, La
csd.edu
ty of California, San Diego, La Jolla, CA,
ifornia, San Diego, La Jolla, CA, 92093-
r, University of California, San Diego, La
uffalo, Buffalo, NY, 14260-1660, USA
n (ESI) available: Synthesis and
ray crystallographic analysis, binding
sRAGE, tabulated data. CCDC
raphic data in CIF or other electronicHS–protein interactions as both therapeutics and research
tools.
The biological function of HSPGs is largely determined
through interactions of the HS chains with protein ligands.
Multiple agents for antagonizing HS–protein interactions have
been developed including heparin mimetic compounds6,7 and
metabolic inhibitors that alter its biosynthesis.8,9 Other
approaches use proteins,10 polypeptides,11,12 foldamers,13,14 or
small molecule antagonists15–18 containing positively charged
residues that bind to the negatively charged carboxylate or
sulfate groups on HS. The accessibility and versatility of small
molecules that antagonize HS–protein interactions make them
particularly attractive as potential research tools and thera-
peutic agents.
We previously identied surfen (1) in the National Cancer
Institute small molecule Diversity Set as an antagonist of HS
and heparin (Fig. 2).19 Binding of surfen to heparin blocks itsFig. 1 Heparan sulfate. A representative octasaccharide segment as
expressed on wild-type CHO-K1 cells is shown.
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinedegradation by bacterial lyases and prevents its ability to acti-
vate antithrombin. In cell culture, surfen inhibits angiogenesis
by preventing the interaction of HS with broblast growth factor
2 (FGF2) and inhibits type I Herpes simplex virus-infection.
Surfen also blocks the enhancement of HIV-1 infection by
amyloid brils found in semen,20,21 alters murine T-cell activa-
tion and proliferation,22 and blocks C5a receptor binding,23
suggesting that some of these processes might also depend on
HS–protein interactions. Surfen also acts independently of HS,
as a trypanocidal agent24 and as an inhibitor of the protease
activity of anthrax lethal factor.25 These diverse properties of
surfen suggest the possibility of designing more selective and
potent analogs to target HS–protein interactions.
To probe the interactions of surfen with HS, identify the key
molecular determinants responsible for its activity, and poten-
tially discover more potent antagonists, a small set of analogs
was synthesized and studied. A structure–activity relationship
was established through quantifying their ability to inhibit cell
surface HS–FGF2 binding in vitro. Certain analogs proved to be
more potent antagonists of HS and were shown to inhibit other
types of HS–protein interactions, including cell surface binding
of soluble RAGE and neutralization of the anticoagulant activity
of unfractionated heparin and low molecular weight heparins
(LMWHs). Importantly, we found that surfen analogs were able
to neutralize both in vitro and in vivo the synthetic penta-
saccharide fondaparinux, for which no antidote exists.26 These
observations imply that small molecule antagonists of HS can
potentially be of therapeutic value and can serve as tools
for chemical biologists interested in probing HS-dependent
cellular processes.Fig. 2 Structures of surfen (1) and its analogs. Modifications highlighted
This journal is © The Royal Society of Chemistry 2015Methodology
Derivative design
Surfen is a symmetric small molecule (MW 372) consisting of
two quinoline moieties linked together through a urea. The
quinoline rings are functionalized with a methyl group at the 2-
position and an exocyclic amine at the 4-position. It has been
previously proposed that the exocyclic amines and urea linker
region of surfen could interact electrostatically with the anionic
carboxylate and sulfate moieties of HS or through hydrogen
bonding.19 It is also possible that the distance between the
aminoquinoline moieties and their orientation are essential for
its biological activity. To examine these possibilities, we
synthesized a series of surfen analogs (Fig. 2).
“Monomeric” versions of surfen, containing a single quino-
line moiety (2, 3), were synthesized to probe the importance of
the dimeric structure of surfen for its biological activity. Here
we refer to these compounds as hemisurfen (2) and acetyl-
hemisurfen (3). A thiocarbonyl analog of surfen (4), referred to
as “thio surfen” in this study, was made with a thiourea core, a
modication that replaces oxygen with larger, less electroneg-
ative sulfur. This substitution should primarily affect the
hydrogen bonding capability of the linker region. To investigate
the importance of the 4-aminopyridine fragment within the
aminoquinoline moieties in binding HS, the exocyclic amines
were replaced by methoxy groups (5) or removed altogether (6).
For simplicity, these compounds are referred to here as
“methoxy surfen” and “deaminated surfen”, respectively. To
assess the signicance of the distance between the amino-
quinoline moieties, the linker between the two heterocycles wasin red and green.
Chem. Sci., 2015, 6, 5984–5993 | 5985
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View Article Onlineextended (7–12) which also increased the hydrophobicity of this
region. Additionally, the urea group was substituted with two
amide bonds. A compound with a glycol-like linker region (13),
trivially named here “diglycolyl surfen”, was synthesized to
probe whether increasing the hydrophilicity of the extended
linker would impact its interaction with HS.
Synthesis
The core heterocycle in surfen, 4,6-diamino-2-methylquinoline
(14), was synthesized as previously reported and was used in the
synthesis of surfen analogs 2–4 and 7–13 (Schemes 1 and 2).27,28
4-Aminoacetanilide (15) was condensed with ethyl acetoacetate
to give ethyl-b-(p-acetamidophenylamino) crotonate (16). ThisScheme 1 Synthesis of 4,6-diamino-2-methylquinoline building
block (14) (a) ethyl acetoacetate, MeOH, reflux, (b) Dowtherm A,
265 C, (c) dimethyl sulfate, toluene, 120 C, (d) ammonium acetate,
135 C, (e) 37% HCl, 90 C.
Scheme 2 Synthesis of surfen derivatives (a) (X¼NH2) potassium cyanate
(X¼NH2) thiophosgene, DMF, rt (d) (X¼OCH3) triphosgene, 1,4-dioxane,
NH2) oxalyl chloride, acetic acid, rt (g) (X¼NH2) malonyl chloride, acetic a
chloride, acetic acid, rt (j) (X ¼ NH2) adipoyl chloride, acetic acid, rt (k) (X ¼
acetic acid, rt.
5986 | Chem. Sci., 2015, 6, 5984–5993ethyl ester intermediate then underwent thermal cyclization in
Dowtherm A to yield 6-acetamide-4-hydroxy-2-methylquinoline
(17). The hydroxyquinoline intermediate was then methylated
with dimethyl sulfate to yield the methoxy derivative (18). This
compound then underwent a two-step reaction to yield 4,6-
diamino-2-methylquinoline (14) through a 6-acetamido-4-ami-
noquinaldine intermediate (19). This building block was used
in the synthesis of specic surfen analogs (4–13) (Schemes 2
and 3).
1,3-Bis(2-methylquinolin-6-yl)urea (deaminated surfen) (6)
was synthesized by reacting triphosgene with the commercially
available 6-amino-2-methylquinoline in acetic acid. Further-
more, compounds 7–13 were synthesized using their respective
diacid chlorides in acetic acid at room temperature. These
compounds (7–13) were named according to the diacid chloride
used in their synthesis. This procedure was adapted from a
previous report.23 4-Amino-2-methyl-6-quinolyl-urea (hemi-
surfen) (2) was prepared using potassium cyanate, 10% acetic
acid, and water followed by recrystallization from water. Finally,
6-acetamido-4-aminoquinaldine (acetyl-hemisurfen) (3) was
synthesized by reacting 4,6-diaminoquinaldine with acetic
chloride in acetic acid, and N,N0-bis-(4-amino-2-methyl-6-qui-
nolyl)-thiourea (thio surfen) (4) was synthesized using thio-
phosgene in DMF. Hemisurfen and acetyl-hemisurfen were
recrystallized from water, while all other nal products were
recrystallized from hot DMF by the addition of diethyl ether. To
synthesize the methoxy analog 1,3-bis(4-methoxy-2-methyl-qui-
nolin-6-yl)urea (methoxy surfen) (5), 6-acetamido-4-methox-
yquinaldine (18) was deprotected with 37% HCl in H2O to form
6-amino-4-methoxyquinaldine (20). This compound was then
reacted with triphosgene to yield 5 (Scheme 3).
Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was
previously obtained from the National Cancer Institute as a
hydrochloride salt (NCI 12155). All compounds were therefore, 10% acetic acid, H2O, rt (b) (X¼NH2) acetyl chloride, acetic acid, rt (c)
acetic acid, rt (e) (X¼H) triphosgene, 1,4-dioxane, acetic acid, rt (f) (X¼
cid, rt (h) (X¼NH2) succinyl chloride, acetic acid, rt (i) (X¼NH2) glutaryl
NH2) pimeloyl chloride, acetic acid, rt (l) (X ¼ NH2) diglycolyl chloride,
This journal is © The Royal Society of Chemistry 2015
Scheme 3 Synthesis of 5 (a) 37% HCl, 90 C, (b) triphosgene, 1,4-
dioxane, acetic acid, rt.
Fig. 3 X-ray crystal structures of (a) surfen$2CF3COOH (1), (b) oxalyl
surfen (7), (c) adipoyl surfen (11), and (d) diglycolyl surfen$2HCl (13).
Counterions and solvent molecules omitted for clarity (see ESI† for
additional information).
Fig. 4 Representative inhibition curves. Surfen (1), oxalyl surfen (7),
and diglycolyl surfen (13) were tested as inhibitors of FGF2 binding.
Table 1 Inhibitory concentrations of surfen and analogs against FGF2
bindinga
Compound IC50 (mM)
Surfen (1) 1.6  0.04
Hemisurfen (2) >100
Acetyl-hemisurfen (3) >100
Thio surfen (4) 8.0  0.20
Methoxy surfen (5) >100
Deaminated surfen (6) >100
Oxalyl surfen (7) 0.9  0.08
Malonyl surfen (8) 1.2  0.03
Succinyl surfen (9) 1.2  0.11
Glutaryl surfen (10) 61.5  0.70
Adipoyl surfen (11) 8.4  1.2
Pimeloyl surfen (12) >100
Diglycolyl surfen (13) 0.7  0.12
a Values represent the mean  SD of n ¼ 3–4 experiments.
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View Article Onlineconverted to their hydrochloride salts for use in biological
assays. The hydrochloride products were precipitated from an
appropriate solvent using 4 M HCl in 1,4-dioxane (Scheme S1†).
The products were analyzed using 1H NMR, 13C NMR, and ESI-
MS. An X-ray crystal structure of one of the analogs (13)
conrmed that these molecules are doubly protonated on their
aminoquinoline ring systems (Fig. 3d). Furthermore, the X-ray
structures of 1 and 13 displayed syn orientations in regards to
their quinoline ring systems (Fig. 3a and d), while the crystal
structures of oxalyl and adipoyl surfen displayed anti orienta-
tions (Fig. 3b and c). These structures suggest that surfen
analogs within this collection could present diverse molecular
congurations that could affect their interactions with the
anionic subunits of HS.Results
Inhibition of HS binding
To determine the potency of surfen and its analogs as HS
antagonists, their ability to inhibit the binding of FGF2 was
quantied in vitro.19 CHO cells express very low levels of FGF
receptors (FGFRs), thus binding primarily occurs through cell
surface HSPGs. Each surfen analog was pre-incubated with
CHO cells. Biotinylated FGF2 was then added, followed by the
addition of uorescently-tagged streptavidin thus forming a
conjugate with cell-bound biotin-FGF2. Flow cytometry was
utilized to monitor the uorescence of bound ligand. FGF
inhibition curves were generated by plotting the percentage of
maximum FGF binding obtained in the absence of any antag-
onist versus the concentration of the molecule of interest (see
Fig. 4 for a representative example). IC50 values were obtained
by tting the dose–response curves to a classic sigmoidal
response (Table 1).This journal is © The Royal Society of Chemistry 2015As shown in Table 1, analogs with oxalyl, malonyl, succinyl
and diglycolyl amide linkers (7–9, 13) showed enhanced inhi-
bition of FGF2 binding to HS compared to surfen (1), the parent
compound. Interestingly, the glutaryl (10) and adipoyl (11)
analogs showed slightly decreased activity compared to native
surfen, while pimeloyl surfen (12) showed minimal inhibitory
activity up to 100 mM. The thiocarbonyl analog (4) showed lower
activity compared to surfen, while the diglycolyl derivative (13)
showed the highest activity. Molecules with modication of the
exocylic amine (5, 6) or that altered the dimeric structure of
surfen (2, 3) were ineffective inhibitors up to 100 mM.
Surfen (1) and the most potent analogs (7, 9, 13) were tested
for the biological relevance of their antagonistic properties by
measuring inhibition of downstream FGF signaling in mouse
embryonic broblasts (MEFs). In line with the binding studies,
all four compounds showed a potent dose-dependent inhibition
of FGF2-induced ERK phosphorylation relative to a control in
the absence of antagonist (Fig. 5).
To explore how analog variations might differentially alter
binding of different proteins to HS we investigated the ability of
surfen-type molecules to antagonize binding of the soluble
ectodomain of RAGE (Receptor for Advanced Glycation End-
products) to HS.29 Succinyl surfen (9) showed dose-dependent
inhibition of binding (IC50 ¼ 1.4  0.2 mM) (Fig. 6a). Acetyl-Chem. Sci., 2015, 6, 5984–5993 | 5987
Fig. 5 Surfen and selected analogs inhibit FGF2-induced ERK phosphorylation. (a) Western blot analysis of the inhibition of downstream FGF-2
induced ERK phosphorylation (p-ERK), (b) band intensities were quantitated by densitometry and plotted as the ratio of p-ERK to ERK signal.
Fig. 6 (a) Succinyl surfen (9) dose-dependently inhibits sRAGE binding
to HS. (b) sRAGE binding inhibitory activity of selected compounds at
10 mM. The values represent the means  SD. *P < 0.0001 compared
with a control in the absence of antagonist.
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
9 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
4/
05
/2
01
8 
13
:4
8:
25
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinehemisurfen (3) showed no inhibitory activity and was used as a
negative control (IC50 > 100 mM).
A full screen of surfen and its derivatives (10 mM) for sRAGE
binding inhibition paralleled the observed trend for FGF2
binding (Fig. S2†). Specically, the more potent FGF2 inhibitors
(e.g. 7–9, 13) also showed high potency for inhibition of sRAGE
binding to cell surface HS, while certain surfen analogs (e.g. 2, 3,
6) showed no inhibitory activity for either protein (Fig. 6b).
Surfen analogs neutralize the anticoagulant activity of heparin
and low molecular weight heparins
Based on their capacity to inhibit HS–protein interactions in
vitro, surfen (1) and the most active analogs (7, 9, and 13) wereFig. 7 Dose-dependent neutralization of (a) unfractionated heparin (UF
were fit using a classic sigmoidal-dose response.
5988 | Chem. Sci., 2015, 6, 5984–5993tested for their ability to neutralize the capacity of unfractio-
nated heparin (UFH) to bind and activate antithrombin III (AT),
a protease inhibitor that blocks the blood coagulation protease
factor Xa. In this assay, heparin binds to AT, induces a confor-
mation change, and triggers the inhibition of factor Xa. Thus,
molecules that prevent heparin from interacting with AT
prevent loss of factor Xa activity, which is readily assessed using
a chromogenic substrate. IC50 values were determined by
varying the concentration of surfen and its analogs. Surfen
yielded an IC50 value of 2  0.06 mM, whereas oxalyl surfen (7),
succinyl surfen (9) and diglycolyl surfen (13) gave IC50 values of
1.2  0.04, 4.6  0.07, and 2  0.03 mM, respectively (Fig. 7).
Selected surfen molecules were also tested as neutralizing
agents of enoxaparin, a lowmolecular weight heparin. Using the
factor Xa assay, we found that surfen, oxalyl surfen, succinyl
surfen, and diglycolyl surfen neutralized enoxaparin in the low
micromolar range (IC50 ¼ 6.4  0.4, 8  0.2, 13.7  2.7, 13.6 
0.6 mM, respectively). These compounds also neutralized fon-
daparinux, a synthetic pentasaccharide, albeit with slightly
lower potency (IC50 ¼ 10.2  0.2, 11.9  0.2, 38.9  2.1, 39.5 
1.6 mM, respectively).Oxalyl surfen neutralizes heparin and fondaparinux in mice
To test if the surfen analogs remained potent and had accept-
able pharmacokinetic properties in vivo, the most potent analogH), (b) enoxaparin (LMWH), (c) fondaparinux (pentasaccharide). Curves
This journal is © The Royal Society of Chemistry 2015
Fig. 8 In vivo neutralization of (a) UFH and (b) fondaparinux in mice (n
¼ 3 for each group). The values represent the means  SD. *P < 0.05
compared with the control group.
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View Article Online(7) was evaluated as a reversal agent for heparin anticoagulant
activity in mice treated with a high anticoagulant dose of either
UFH or fondaparinux (Fig. 8). UFH at 1200 IU kg1 (>5-fold the
therapeutic dose) was injected subcutaneously and, aer 1
hour, oxalyl surfen (6 mg kg1) or vehicle control were injected
intravenously. Protamine (16 mg kg1) was used for compar-
ison. Aer 5 minutes, blood was collected, centrifuged, and the
plasma was isolated and analyzed for FXa activity. A calibration
curve was established to determine the amount of active UFH or
fondaparinux that remained. The concentration of UFH in the
plasma was found to be signicantly reduced in the oxalyl
surfen-treated (0.08  0.001 IU mL1) and protamine-treated
(0.09  0.01 IU mL1) groups compared to the control mice
(1.46  0.9 IU mL1) (Fig. 8a). In a similar experiment, 0.5 mg
kg1 fondaparinux (ca. 5-fold the therapeutic dose) was injected
subcutaneously, and aer 10 minutes, protamine (16 mg kg1),
oxalyl surfen (16 mg kg1) or vehicle control were injected
intravenously. Fondaparinux in plasma was signicantly
reduced in oxalyl surfen-treated mice compared to the control-
treated group (0.14  0.06 mg L1 vs. 2.1  0.33 mg L1,
respectively) and was equivalent to a 93 2.8% decrease in anti-
FXa activity (Fig. 8b). As previously reported,22 we found prot-
amine ineffective in neutralizing fondaparinux in vivo. The
results demonstrate that oxalyl surfen can reverse the antico-
agulant activity of fondaparinux in vitro and in vivo and thus has
the potential to be developed as an antidote in humans.
Discussion
Surfen, a dimeric quinoline-containing molecule found in the
NCI compound database, was recently described as a small
molecule antagonist of certain HS–protein interactions.19 The
nature of the interaction between surfen and HS is not,
however, fully understood. To shed light on its interactions with
HS and to identify more potent antagonists, several strategically
modied surfen analogs were synthesized. Their ability to
inhibit the binding of FGF2 to cell-surface HS on wild-type CHO
cells was quantied to generate structure–activity relationships.
FGF2, a potent mitogen and member of the heparin-binding
growth factor family, has been shown to preferentially bind to
N-sulfated, 2-O-sulfated sites of cell surface and extracellular
matrix HS (Fig. 1).30,31 Due to the strong affinity of FGF2 for HS,
this assay served as a useful tool to assess the ability of small
molecules to antagonize these essential interactions. AllThis journal is © The Royal Society of Chemistry 2015derivatives were also tested as antagonists of soluble RAGE
(sRAGE) protein binding to HS and as neutralizing agents of
heparin and low molecular weight heparins.
In general, surfen analogs with the dimeric aminoquinoline
moiety intact showed a dose-dependent inhibition of FGF2
binding similar to that of surfen (Table 1). Analogs lacking the
exocyclic amines on the quinoline ring systems (e.g., 5, 6)
showed low inhibitory activity (IC50 > 100 mM). The lack of
improvement in binding seen in these derivatives with modi-
cations at the 4-position is not surprising. The protonated form
of 4-aminoquinoline was previously shown to display lower
acidity (pKa  8.5) compared with aminoquinoline derivatives
substituted at other positions.32 Similarly, the basic 4-amino-
quinoline moieties of surfen, upon protonation, can electro-
statically interact with the negatively charged sulfate and
carboxyl groups of HS via hydrogen bonding (Scheme S1†).
Hemisurfen (2) and acetyl-hemisurfen (3) did not inhibit
FGF2 binding. These derivatives only contain one amino-
quinoline moiety, while maintaining a urea or an amide unit
mimicking the linker region. The lack of activity of these
“monomeric” forms of surfen suggests a critical role for the
dimeric structure of the parent molecule. A similar effect was
observed recently with adhesamine, a small molecule that
enhances cell adhesion through interactions with HS.33 It is
possible that the three dimensional arrangement, length, or
valency of surfen-type antagonists could affect their activity and
interaction with HS. Investigation of multivalent analogs of HS-
binding molecules reported cooperative and enhanced binding
to HS upon increasing the number of cationic HS-binding
moieties.34,35 These ndings suggest that surfen analogs that
display multiple aminoquinoline moieties might exhibit
enhanced binding to HS as well.
Certain analogs with extended linkers (e.g., 7–9, 13), where
the central urea moiety was replaced with a diamide linker,
showed enhanced ability to inhibit FGF2 binding to HS
compared to surfen. Similarly, these compounds also blocked
binding of sRAGE to HS. Enhancing the H-bonding ability and
spreading of the aminoquinoline recognition domains may
account for enhanced potency, as engagement with additional
sites along the long and heterogeneous HS chains might occur.
The enhanced inhibitory activity of the oxalyl (7), malonyl (8),
and succinyl (9) analogs compared to surfen (1) supports this
idea. Interestingly, extending the linker region further (e.g., 10–
12) hinders the interaction with HS and lowers the inhibitory
activity, possibly due to their more hydrophobic nature. A
similar loss of activity of derivatives with longer linker regions
has been previously observed in a study of surfen-type
compounds as inhibitors of anaphylatoxic C5a receptor.23 Due
to the decreased activity of derivatives with more hydrophobic
linkers, an analog with a more hydrophilic linker region,
diglycolyl surfen (13), was synthesized. Diglycolyl surfen proved
to be most potent in regards to inhibition of FGF2 binding to
HS, suggesting that adding additional H-bonding sites to the
linker region enhances the interaction with HS.
The observations discussed above correlating activity and
linker lengths are not necessarily universal since the adipoyl
surfen analog (11) showed better inhibitory activity compared toChem. Sci., 2015, 6, 5984–5993 | 5989
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View Article Onlinethe glutaryl and pimeloyl analogs (10 and 12, respectively).
Other reports have shown that the conformation of the binding
domains of certain proteins is critical for their interaction with
the anionic sugar residues of glycosaminoglycans, such as
HS.36,37 In a similar way, it is possible that even-numbered
linkers, due to preferred hydrocarbon conformation and impact
on the projection of the heterocycles, display a more favorable
molecular conguration for binding to HS compared to odd
numbered linkers.
To assess the signicance of the urea core, it was modied to
a thiourea, while the rest of the structure was kept intact.
Although a minor modication in regards to the entire molec-
ular structure, the thio surfen analog (4) displayed lower FGF
inhibitory potency compared to surfen, due to altered hydrogen
bonding.38,39 Consequently, thio surfen is a less active HS
antagonist compared to surfen, although it remains a micro-
molar inhibitor under the conditions of our assays.
Surfen (1) and the most potent compounds (7, 9, 13) were also
able to dose-dependently antagonize downstream FGF signaling
in MEFs. FGF2 signaling is dependent on the formation of a
ternary complex between FGF, FGFR, and HS at the cell surface
and initiates an intracellular signaling cascade leading to phos-
phorylation of ERK. These results are in line with previous
observations using surfen (1) in endothelial cells19 and provide
strong support for the biological relevance of surfen-type
compounds as HS antagonists (Fig. 5). Variation in efficacy as
compared to simple binding to FGF2may be due to simultaneous
inhibition of HS interaction with receptor as well as the ligand.
A screen of the entire library of surfen compounds for their
ability to inhibit soluble RAGE (sRAGE) binding to cell surface
HS revealed a similar potency trend to the FGF2 binding inhi-
bition experiments (Fig. S2†). These results suggest that analog
variations seem to similarly affect the binding properties of
different HS ligands.
Heparin, a highly sulfated form of HS, binds to antithrombin
III (AT), a serine protease inhibitor found in the coagulation
cascade, and facilitates a conformational change that accelerates
the inhibition of coagulation factors such as factor Xa and
thrombin.40 Heparin has been used as an anticoagulant agent in
surgery and treatment for certain thrombotic diseases for many
years. However, adverse side effects can occur in some patients
including excessive bleeding and thrombocytopenia.41Numerous
agents have been developed over the years to neutralize
heparin.13,14,42–47 Currently, protamine, a mixture of arginine-rich
proteins (MW  5000) is approved therapeutically for reversing
the action of heparin in patients. However, protamine has dis-
played adverse side effects in some patients and demonstrates
low efficacy towards reversing more recently developed low
molecular weight heparins (LMWH), such as enoxaparin, and it
is ineffective in neutralizing fondaparinux, a synthetic penta-
saccharide analog of heparin.48–53
Interestingly, selected surfen analogs showed complete
neutralization of unfractionated heparin (UFH), LMWH (enox-
aparin) and the synthetic pentasaccharide (fondaparinux) both
in vitro and in vivo (Fig. 7). Surfen (1) and oxalyl surfen (7) dis-
played the highest potency against each heparinoid (micro-
molar range), while succinyl surfen (9) had the lowest activity.5990 | Chem. Sci., 2015, 6, 5984–5993Diglycolyl surfen (13) showed high activity against UFH
compared to native surfen, while displaying inferior activity
against LMWH. It appears that analogs with longer linker
regions (9, 13) display lower activity against LMWH compared to
surfen and oxalyl surfen (1, 7). All four surfen analogs tested
show a potency trend of UFH > enoxaparin > fondaparinux,
suggesting that neutralization may depend on the number of
potential binding sites in the substrate. Although not studied
here, we suspect that surfen molecules could align along each
negatively-charged sugar chain in a cooperative manner and
block the necessary AT binding sites. Regardless of their
mechanism, these ndings suggest that surfen analogs, such as
oxalyl surfen, could be an alternative for protamine and can be
further developed as a therapeutic agent.Conclusions
In this study, a collection of surfen analogs was synthesized to
illuminate their interaction with HS and to look for more potent
HS antagonists. A cell culture-based structure–activity rela-
tionship, generated by monitoring the inhibition of FGF2
binding, suggests that the dimeric structure, exocyclic amines,
and urea linker region play essential roles in the interaction of
surfen with HS. Conserving the dimeric aminoquinoline
moieties preserved the biological activity of the molecule, while
certain modications to the linker region either lowered or
enhanced their antagonistic properties suggesting the hydrogen
bonding capability of the linker as well as the separation and
orientation of the heterocycles can impact the interaction with
HS. Some extended analogs of surfen proved to be more potent
antagonists of FGF2 binding to HS. Furthermore, these mole-
cules were shown to dose-dependently antagonize the HS-
binding of soluble RAGE protein and neutralize UFH and
LMWH in a factor Xa chromogenic assay. Finally, a potent
surfen analog was shown to neutralize heparin and fondapar-
inux in vivo in mice. Taken together, these ndings illustrate the
potential of small molecules as antagonists of HS and raise the
possibility of using surfen-type compounds to serve as
biochemical tools and as potential effectors in disorders that
involve glycosaminoglycan–protein interactions.Experimental section
Mice
Eight-week old C57BL/6 mice were purchased from Charles
Rivers Laboratories. All animals were housed in barrier condi-
tions in the vivaria of the School of Medicine of the University of
California San Diego that were approved by the Association for
Assessment and Accreditation of Laboratory Animal Care. All
procedures were approved by the local Animal Care Program.
Mice were maintained on a 12 hour light–dark cycle, and were
fed ad libitum water and PicoLab 5053 rodent chow.Materials
Unless otherwise specied, materials purchased from commer-
cial suppliers were used without further purication. Surfen (bis-This journal is © The Royal Society of Chemistry 2015
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View Article Online2-methyl-4-amino-quinolyl-6-carbamide) was obtained from the
Open Chemical Repository in the Developmental Therapeutic
Program of the National Cancer Institute (NSC 12155). All other
anhydrous solvents and reagents were purchased from Sigma-
Aldrich, with the exception of 4 M HCl in 1,4-dioxane (Alfa-Aesar)
and 6-amino-2-methylquinoline (Acros Organics). NMR solvents
were purchased from Cambridge Isotope Laboratories (Andover,
MA). FGF2 (E. coli recombinant) was purchased from Peprotech,
and the sulfo-NHS-LC-biotin linker was purchased from Thermo
Scientic. PBS (Dulbecco's phosphate buffered saline), F12
Media, Cell Dissociation Buffer (PBS-based, Enzyme Free), and
streptavidin-Cy5 were purchased from Life Technologies (Carls-
bad, CA). FACS buffer (isotonic solution 0.85% w/v, phosphate
buffered pH 7.1–7.3) and streptavidin-PE-Cy5 were purchased
from BD Biosciences. Trypsin/EDTA was purchased from VWR
(Mediatech). Tissue culture plates (20 mm) were from BD Falcon
(BD Biosciences). Heparin (Scientic Protein Laboratories, 188.9
IU mg1), enoxaparin sodium (Lovenox®, 100 mg mL1) and
fondaparinux sodium (Arixtra®, 5 mg mL1) were obtained
from their manufacturers. Salmon protamine (Grade IV) was
purchased from Sigma-Aldrich.
Instrumentation
NMR spectra were recorded on Varian Mercury 300 and 400
MHz, and Varian VX 500 MHz spectrometers. Mass spectra were
recorded at the UCSD Chemistry and Biochemistry Mass Spec-
trometry Facility, utilizing an Agilent 6230 HR-ESI-TOF mass
spectrometer. Flow cytometry studies were performed on a BD
FACSCalibur. Absorbance measurements for the factor Xa assay
were performed on a VersaMax microplate reader (Molecular
Devices) using Somax Pro soware.
Synthesis
Full synthetic procedures and characterization of all
compounds can be found in the ESI.†
FGF2 and sRAGE binding inhibition
Wild-type CHO cells (ATCC CCL-61) were grown in F12 growth
medium supplemented with 10% (v/v) fetal bovine serum, 100
mg mL1 of streptomycin sulfate, and 100 units per mL of
penicillin G. Cells were grown to conuence, lied with Cell
Dissociation Buffer, washed with PBS buffer, and pre-incubated
with specic concentrations of surfen or surfen analog in PBS/
0.1% BSA on ice for 10 min. Next, biotinylated FGF2 (2.5 nM,
1 : 1000) or biotinylated sRAGE (2 mg mL1, 1 : 100) (ESI†) were
added and incubated for 30 min or 1 hour on ice, respectively.
Cells were washed, and bound biotinylated protein was detected
by using streptavidin-PE-Cy5 or streptavidin-Cy5 (1 : 1000,
PharMingen) and ow cytometry (FacsCalibur, BD Biosciences).
Certain compounds (1, 4, 5, 7) required use of streptavidin-Cy5
due to interference. Raw data was interpreted using FlowJo
Analytical Soware (Tree Star Inc.). Protein binding was quan-
tied by the geometric mean of the uorescence intensity.
Results are represented as the extent of binding compared with
a sample incubated in the absence of surfen. These values were
later plotted and further analyzed using GraphPad Prism v5.0.This journal is © The Royal Society of Chemistry 2015Stock solutions were made for each compound in DMSO (30
mM). For each experiment, the stock solutions were diluted rst
to 10 mM DMSO, then the appropriate serial dilutions were
made in PBS buffer (with 0.1% BSA). Stock solutions for analogs
7 and 11 were made in 1 : 1 DMSO–H2O mixture to improve
their solubility. Stock solutions were made and stored in glass
containers because surfen has been previously found to bind to
plastic. Compounds and DMSO stock solutions were stored
under argon at 20 C.
FGF2 signaling
For signaling assays, immortalized mouse embryonic broblast
cells were cultured in 12-well plates. The growth medium was
exchanged for serum-free DMEM (Invitrogen) for 5 hours before
the addition of surfen or surfen analog. Cells were incubated
with compounds for 10 min at 37 C. Subsequently, FGF2
(20 ng mL1) was added for 5 min then cells were put on ice,
washed with ice-cold PBS, and lysed using ice-cold radio-
immunoprecipitation assay buffer. Protein concentration was
determined using the Pierce BCA Protein Assay Kit (Thermo
Scientic) before Western blot analysis. Cells were resolved by
SDS-PAGE and blotted with antiphospho-ERK and anti ERK
antibodies (Cell Signaling Technology) at 1 : 1000 dilutions.
Bands were visualized on an Odyssey Infrared imaging system
(Li-Cor Biosciences) as described.54 Band intensities were
quantitated by densitometry using Image J soware.
Factor Xa inhibition assay
Human antithrombin III (66 mg mL1; Enzyme Research Labo-
ratories), heparin or heparinoid (0.2 IU mL1), and various
concentrations of surfen or surfen analog were prepared in a
solution containing 25 mM HEPES (N-[2-hydroxyethyl] pipera-
zine-N0-[2-ethanesulfonic acid]), 150 mM NaCl and 0.1% bovine
serum albumin (pH 7.5) in a 96-well microtiter plate. Human
factor Xa (0.4 mg mL1, 50 mL; Enzyme Research Laboratories)
was added to each well and the solutions were incubated for 10
min at room temperature with frequent mixing. Chromogenic
substrate specic for factor Xa (0.5 mg mL1, 50 mL; S-2765
Diapharma) was added, incubated for 5 min at room tempera-
ture, and absorbance was measured at 405 nm. Background
absorption at 405 nm was subtracted prior to analysis of the
results. A heparin/heparinoid concentration with approximately
85% factor Xa inhibition was selected for measurement of
neutralization (0.2 IU per well). Results are represented as the
extent of factor Xa activity compared with a sample incubated
with heparin/heparinoid in the absence of surfen. Surfen and
analogs had no direct effect on factor Xa activity measured in
the absence of heparin.
In vivo heparin neutralization
Wild-type mice (8 weeks old, weight  20–30 g) were divided
into a control group (n ¼ 3), an oxalyl surfen-treated group (n ¼
3), and a protamine-treated group (n ¼ 3). Thirty min before
heparin administration, a blood sample was collected by tail
bleeding in 3.2% sodium citrate tubes (9 : 1 blood to citrate
ratio). Each mouse received a subcutaneous injection of UFHChem. Sci., 2015, 6, 5984–5993 | 5991
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View Article Online(1200 IU kg1, PBS) or fondaparinux (0.5 mg kg1, PBS). Next,
mice received an intravenous injection (via tail vein) of DMSO–
H2O solution (control), protamine (16 mg kg
1, PBS), or oxalyl
surfen (6 or 16 mg kg1, DMSO–water) 60 min aer UFH and 10
min aer fondaparinux administration. Five min aer admin-
istration of the reversal compound, blood was collected via
submandibular bleeds into 3.2% sodium citrate tubes. Plasma
was collected immediately (2200 g for 15 min) and stored at
80 C. A heparin anti-FXa colorimetric assay was used to
analyze the neutralization effect of protamine and oxalyl surfen
(7). Their activity was compared to a heparin control without
reversal agent as described above. The change in the absorption
at 405 nm for each sample was compared with a standard
calibration curve to determine the amount of heparin present.
The purpose of this assay is to analyze the amount of UFH or
fondaparinux remaining in plasma by indirectly measuring the
residual activity of FXa. Heparinized plasma (3 mL) was mixed
with antithrombin, forming an AT–heparin complex. The
amount of UFH or fondaparinux remaining in plasma was
plotted against the reversal agent dosage.Acknowledgements
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